Form 4 Filing for Black Diamond Therapeutics, Inc.

This filing details a Form 4 filed by Kapil Dhingra, a director at Black Diamond Therapeutics, Inc. (BDTX). On June 26, 2026, Dhingra acquired 40,000 stock options with a purchase price of $0.00 per share. These options are for the company's Common Stock. The options will vest and become exercisable in full on the earlier of June 26, 2027, or the issuer's next annual meeting of stockholders, contingent upon Dhingra's continued service. The exercise price for these options is $1.71 per share. Following this transaction, Dhingra holds 40,000 shares directly. The filing was signed on June 29, 2026, by Brent Hatzis-Schoch as Attorney-in-Fact.